List/Grid Tag Archives: clinical

Schroeder named Associate Dean for Clinical Affairs and Vice President for Physician Integration

Schroeder named Associate Dean for Clinical Affairs and Vice President for Physician Integration

September 25, 2013 James L. Schroeder, MD, MBA, a physician with expertise relating to health care reimbursement, quality and contracting, as well as in ambulatory practice management, has been named associate dean for clinical affairs and vice president for physician integration at the University of Chicago Medicine, effective October 1, 2013.

Voyantlink™ By Brainlab Enables Hospitals And Surgeons To Move Beyond Image Sharing And Into Enhanced Decision-making

Voyantlink™ By Brainlab Enables Hospitals And Surgeons To Move Beyond Image Sharing And Into Enhanced Decision-making

CHICAGO , Nov. 27, 2011 /CHICAGOPRESSRELEASE.COM/ — Brainlab announced today the launch of VoyantLink™, a cloud-based image sharing, viewing, and enrichment platform for clinicians, hospitals and imaging centers at the Radiological Society of North America (RSNA).

AAOS Issues New Clinical Practice Guideline for Treating Common Elbow Fractures in Children

AAOS Issues New Clinical Practice Guideline for Treating Common Elbow Fractures in Children

Guidelines outline steps to stabilize the injury and treat complications ROSEMONT, Ill. , Nov.

First MacLean Center Prize in Clinical Ethics awarded to Dartmouth’s John Wennberg

First MacLean Center Prize in Clinical Ethics awarded to Dartmouth’s John Wennberg

November 16, 2011 The MacLean Center for Clinical Medical Ethics at the University of Chicago awarded the first MacLean Center Prize in Clinical Ethics and Health Outcomes to John E. Wennberg, MD, MPH, the Peggy Y.

Bucksbaum Foundation pledges $42 million to bolster doctor-patient communication

Bucksbaum Foundation pledges $42 million to bolster doctor-patient communication

September 22, 2011 View a video about the Bucksbaum Institute for Clinical Excellence. The Matthew and Carolyn Bucksbaum Family Foundation is giving $42 million to the University of Chicago to create the Bucksbaum Institute for Clinical Excellence, a unique initiative that will focus on how to improve doctor-patient interaction.

New drug aids gout patients not helped by standard treatments

New drug aids gout patients not helped by standard treatments

Pegloticase, a modified porcine enzyme, can produce significant and sustained clinical improvements in two out of five patients with chronic gout that is resistant to conventional therapies, researchers report in the Aug. 17 issue of JAMA .

Many patients with advanced cancers get treatments that won’t help

Many patients with advanced cancers get treatments that won’t help

June 7, 2011 A study of more than 1,000 patients with colon cancer that had spread to distant sites found that one in eight was treated with at least one drug regimen that was not recommended. Those patients were exposed to significant risk without proven benefits, at an estimated cost — just for the drugs — of more than $2 million.

President Obama names Olopade to National Cancer Advisory Board

President Obama names Olopade to National Cancer Advisory Board

March 2, 2011 President Barack Obama on Feb. 24 announced his intent to appoint Olufunmilayo Falusi Olopade , the Walter L.

Alexian Brothers Medical Center Named One of ‘America’s 50 Best Hospitals’ for 2011

Alexian Brothers Medical Center Named One of ‘America’s 50 Best Hospitals’ for 2011

ARLINGTON HEIGHTS, Ill. , Feb.

Abbott’s XIENCE V® Shows Outstanding Two-Year Clinical Results Versus TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Trial

Abbott’s XIENCE V® Shows Outstanding Two-Year Clinical Results Versus TAXUS® in Key Safety and Efficacy Measures in SPIRIT IV Trial

— XIENCE V Shows Clinically Significant 30 Percent Risk Reduction Through Two Years in Composite Endpoint of Target Lesion Failure Compared to TAXUS — Excellent Two-Year Safety Data Reported; 64 Percent Risk Reduction in ARC Stent Thrombosis (Blood Clots) Compared to TAXUS — Two-Year Results from SPIRIT IV Demonstrate Continued Safety and Efficacy of XIENCE V With Consistent Benefits in Complex Subgroups(1) ABBOTT PARK, Ill., Sept. 23 /CHICAGOPRESSRELEASE.COM/ — Late-breaking data from the SPIRIT IV trial, one of the largest randomized clinical trials between two drug eluting stents, continued to demonstrate outstanding clinical results of Abbott’s (NYSE: ABT ) market-leading XIENCE V® Everolimus Eluting Coronary Stent System versus the TAXUS® Express2™ Paclitaxel-Eluting Coronary Stent System (TAXUS) in key areas of safety and efficacy through two years.

© 2017 Chicago Press Release Services.
All rights reserved. XHTML / CSS Valid.